Global Extended Release Drug 麻豆原创 Research Report 2023

Publication ID:

PB503232801

Publication Date:

March 9, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Drug delivery systems are engineered technologies for controlled release of drugs or to the targeted delivery of drugs. Drug delivery system is a kind of formulation that enables the administration of therapeutic agents in the body and improves its safety and efficacy by controlling the time, rate and place of drug release in the body. Most of the conventional oral products of drugs are formulated to release the active ingredient as soon as it is administered. Now the pattern has been changed to modified release dosage forms to achieve better therapeutic target.听Extended release drugs听is a type of dosage forms which allows a two-fold reduction in frequency of dosage administered in the body.
Highlights
The global Extended Release Drug market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Extended Release Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Extended Release Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Extended Release Drug in Hospital Pharmacy is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Extended Release Drug include Pfizer, Mallinckrodt, Teva, Johnson & Johnson, Endo Pharmaceuticals, Purdue Pharma, Mylan, Hisamitsu Pharmaceutical and Sun Pharmaceutical Industries, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Extended Release Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Extended Release Drug.
The Extended Release Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Extended Release Drug market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Extended Release Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Pfizer
Mallinckrodt
Teva
Johnson & Johnson
Endo Pharmaceuticals
Purdue Pharma
Mylan
Hisamitsu Pharmaceutical
Sun Pharmaceutical Industries
Segment by Type
Sustained Release Drug
Controlled Release Drug
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Extended Release Drug companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Extended Release Drug 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Sustained Release Drug
1.2.3 Controlled Release Drug
1.3 麻豆原创 by Application
1.3.1 Global Extended Release Drug 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Extended Release Drug 麻豆原创 Perspective (2018-2029)
2.2 Extended Release Drug Growth Trends by Region
2.2.1 Global Extended Release Drug 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Extended Release Drug Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Extended Release Drug Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Extended Release Drug 麻豆原创 Dynamics
2.3.1 Extended Release Drug Industry Trends
2.3.2 Extended Release Drug 麻豆原创 Drivers
2.3.3 Extended Release Drug 麻豆原创 Challenges
2.3.4 Extended Release Drug 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Extended Release Drug Players by Revenue
3.1.1 Global Top Extended Release Drug Players by Revenue (2018-2023)
3.1.2 Global Extended Release Drug Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Extended Release Drug 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Extended Release Drug Revenue
3.4 Global Extended Release Drug 麻豆原创 Concentration Ratio
3.4.1 Global Extended Release Drug 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Extended Release Drug Revenue in 2022
3.5 Extended Release Drug Key Players Head office and Area Served
3.6 Key Players Extended Release Drug Product Solution and Service
3.7 Date of Enter into Extended Release Drug 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Extended Release Drug Breakdown Data by Type
4.1 Global Extended Release Drug Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Extended Release Drug Forecasted 麻豆原创 Size by Type (2024-2029)
5 Extended Release Drug Breakdown Data by Application
5.1 Global Extended Release Drug Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Extended Release Drug Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Extended Release Drug 麻豆原创 Size (2018-2029)
6.2 North America Extended Release Drug 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Extended Release Drug 麻豆原创 Size by Country (2018-2023)
6.4 North America Extended Release Drug 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Extended Release Drug 麻豆原创 Size (2018-2029)
7.2 Europe Extended Release Drug 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Extended Release Drug 麻豆原创 Size by Country (2018-2023)
7.4 Europe Extended Release Drug 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Extended Release Drug 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Extended Release Drug 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Extended Release Drug 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Extended Release Drug 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Extended Release Drug 麻豆原创 Size (2018-2029)
9.2 Latin America Extended Release Drug 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Extended Release Drug 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Extended Release Drug 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Extended Release Drug 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Extended Release Drug 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Extended Release Drug 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Extended Release Drug 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Extended Release Drug Introduction
11.1.4 Pfizer Revenue in Extended Release Drug Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 Mallinckrodt
11.2.1 Mallinckrodt Company Detail
11.2.2 Mallinckrodt Business Overview
11.2.3 Mallinckrodt Extended Release Drug Introduction
11.2.4 Mallinckrodt Revenue in Extended Release Drug Business (2018-2023)
11.2.5 Mallinckrodt Recent Development
11.3 Teva
11.3.1 Teva Company Detail
11.3.2 Teva Business Overview
11.3.3 Teva Extended Release Drug Introduction
11.3.4 Teva Revenue in Extended Release Drug Business (2018-2023)
11.3.5 Teva Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Extended Release Drug Introduction
11.4.4 Johnson & Johnson Revenue in Extended Release Drug Business (2018-2023)
11.4.5 Johnson & Johnson Recent Development
11.5 Endo Pharmaceuticals
11.5.1 Endo Pharmaceuticals Company Detail
11.5.2 Endo Pharmaceuticals Business Overview
11.5.3 Endo Pharmaceuticals Extended Release Drug Introduction
11.5.4 Endo Pharmaceuticals Revenue in Extended Release Drug Business (2018-2023)
11.5.5 Endo Pharmaceuticals Recent Development
11.6 Purdue Pharma
11.6.1 Purdue Pharma Company Detail
11.6.2 Purdue Pharma Business Overview
11.6.3 Purdue Pharma Extended Release Drug Introduction
11.6.4 Purdue Pharma Revenue in Extended Release Drug Business (2018-2023)
11.6.5 Purdue Pharma Recent Development
11.7 Mylan
11.7.1 Mylan Company Detail
11.7.2 Mylan Business Overview
11.7.3 Mylan Extended Release Drug Introduction
11.7.4 Mylan Revenue in Extended Release Drug Business (2018-2023)
11.7.5 Mylan Recent Development
11.8 Hisamitsu Pharmaceutical
11.8.1 Hisamitsu Pharmaceutical Company Detail
11.8.2 Hisamitsu Pharmaceutical Business Overview
11.8.3 Hisamitsu Pharmaceutical Extended Release Drug Introduction
11.8.4 Hisamitsu Pharmaceutical Revenue in Extended Release Drug Business (2018-2023)
11.8.5 Hisamitsu Pharmaceutical Recent Development
11.9 Sun Pharmaceutical Industries
11.9.1 Sun Pharmaceutical Industries Company Detail
11.9.2 Sun Pharmaceutical Industries Business Overview
11.9.3 Sun Pharmaceutical Industries Extended Release Drug Introduction
11.9.4 Sun Pharmaceutical Industries Revenue in Extended Release Drug Business (2018-2023)
11.9.5 Sun Pharmaceutical Industries Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer
Mallinckrodt
Teva
Johnson & Johnson
Endo Pharmaceuticals
Purdue Pharma
Mylan
Hisamitsu Pharmaceutical
Sun Pharmaceutical Industries

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.